Azelis news release

REGULATED INFORMATION

19 May 2026

Transparency notification from UBS Group AG

Antwerp (Belgium), 19 May 2026 – 17:45 CET – In accordance with Article 14 of the Belgian Transparency law of 2 May 2007, Azelis Group NV announces that on 18 May 2026, it has received a transparency notification from UBS Group AG.

1. *Summary of the notification*

UBS Group AG reported in its notification dated 18 May 2026, that on 13 May 2026, following an acquisition of equivalent financial instruments, UBS Group AG (taking into account the holding of all its affiliates), increased its holdings in equivalent financial instruments and crossed the threshold of 3.00% in Azelis Group NV.

On 13 May 2026, UBS Group AG (taking into account the holding of all its affiliates) owned 451,015 shares with voting rights, representing 0.18% of the total number of shares issued by the company (243,921,719), versus 643,290 shares representing 0.26% in its previous notification dated 1 May 2026, as well as 7,318,352 equivalent financial instruments, representing 3.00% of the voting rights issued by the company, versus 6,932,000 equivalent financial instruments, representing 2.84% in its previous notification dated 1 May 2026.

2. *Content of the notification*

Reason for the notification

Acquisition or disposal of voting securities or voting rights

Notification by

A parent undertaking or a controlling person

Persons subject to the notification requirement

Name	Address (for legal entities)
UBS Group AG	Bahnhofstrasse 45, 8001 Zürich

Date on which the threshold is crossed

13 May 2026

Threshold that is crossed (in %)

3%

Denominator

243,921,719

Notified Details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
UBS Group AG	0	0	0	0.00%	0.00%
UBS AG	272,130	43,725	0	0.02%	0.00%
UBS Asset Management (Europe) S.A.	96,614	96,614	0	0.04%	0.00%
UBS Asset Management Life Limited	8,128	8,128	0	0.00%	0.00%
UBS Fund Management (Switzerland) AG	241,418	277,548	0	0.11%	0.00%
UBS Securities LLC	25,000	25,000	0	0.01%	0.00%
Subtotal	643,290	451,015		0.18%	
	TOTAL	**451,015**	**0**	**0.18%**	**0.00%**

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement

Innovation through formulation

UBS AG	Long Call Option	17/12/2027		177,000	0.07%	physical
UBS AG	Long Call Option	17/03/2028		61,500	0.03%	physical
UBS AG	Equity Swaps	28/03/2028		630	0.00%	cash
UBS Switzerland AG	Right of use over shares		At any time	1,770,592	0.73%	physical
UBS AG	Right of use over shares		At any time	122,571	0.05%	physical
UBS AG	Right to Recall of Lent shares		At any time	620,429	0.25%	physical
UBS Switzerland AG	Right to Recall of Lent shares		At any time	3,975,320	1.63%	physical
UBS AG	Right to Substitute shares delivered as collaterals		At any time	590,310	0.24%	physical
	TOTAL			7,318,352	3.00%	

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	7,769,367	3.19%

Chain of controlled undertakings through which the holding is effectively held, if applicable

Please see full chain of control attached.

Additional information

The disclosure obligation arose due to the indirect holdings in financial instrument of UBS Group AG in voting rights of Azelis Group NV, held directly by controlled undertakings, going above 3% on 13th May 2026.

3. *Further information*

The full transparency notification as well as this press release can be consulted on the Azelis Group NV’s website.

………………… END …………………

Innovation through formulation

Contact information:

Azelis
investor-relations@azelis.com

About Azelis

Azelis is the reference global innovation service provider in the speciality chemical and food ingredients industry, present in 64 countries across the globe with over 4,100 employees. Our knowledgeable teams of industry, market and technical experts are each dedicated to a specific market within Life Sciences and Industrial Chemicals. We offer a comprehensive portfolio of complementary products to more than 65,000 customers, supported by +2,800 principal relationships, creating a turnover of €4.1 billion (2025). Azelis Group NV is listed on Euronext Brussels under ticker AZE and is included in the BEL20 and BEL®ESG indices.

Across our extensive network of more than 70 application laboratories, our award-winning teams develop innovative and sustainable formulations and provide technical guidance throughout the product development process. We combine global market reach with a local footprint to offer reliable, integrated, and unique digital services to local customers and attractive business opportunities to principals. Recognised for our sustainability leadership, we are committed to responsible growth that positively impacts people, communities and the planet. Through the application of science and deep market expertise, we act as catalysts for innovation, enabling our customers to win and our principals to grow.

Innovation through formulation.

www.azelis.com

Innovation through formulation

Attachment – Chain of control

11. Information in relation to the person subject to the notification obligation – organizational
UBS Group AG
UBS AG
UBS Asset Management AG
UBS Asset Management (Europe) S.A.
-
UBS Group AG
UBS AG
UBS Asset Management AG
UBS Asset Management Holding (No. 2) Ltd
UBS Asset Management Holding Ltd
UBS Asset Management Life Ltd
-
UBS Group AG
UBS AG
UBS Asset Management AG
UBS Asset Management Switzerland AG
UBS Fund Management (Switzerland) AG
-
UBS Group AG
UBS AG
UBS Americas Holding LLC
UBS Americas Inc.
UBS Securities LLC
-
UBS Group AG
UBS AG
UBS Switzerland AG

Innovation through formulation